Table 4.
Pharmacokinetic Parameters of Ritonavir, With and Without Etravirine*
| Ritonavir PK Parameters | Darunavir/Ritonavir | Darunavir/Ritonavir Plus Etravirine (Group 2) |
|
|---|---|---|---|
| (Group 1) | Etravirine 200 mg Twice-Daily (Group 2A) |
Etravirine 400 mg Once-Daily (Group 2B) | |
| N | 16 | 5‡ | 7§ |
| AUC24 (mg × h/L) | 4.4 (3.5–5.5) | 5.2 (1.7–16.2) | 4.4 (3.4–5.8) |
| Cmax (mg/L) | 0.6 (0.4–0.7) | 0.6 (0.2–2.0) | 0.6 (0.4–0.8) |
| T1/2 (h) | 4.8 (4.2–5.4)¶ | 9.5 (2.3–40.1) | 4.7 (3.5–6.3)[dbar] |
| CL/F (L/h) | 22.8 (18.1–28.6) | 19.3 (6.2–60.6) | 22.3 (17.1–29.2) |
| V/F (L) | 135.6 (109.8–167.5) | 265.2 (139.07–505.9) | 139.6 (87.7–222.3) |
Abbreviations: AUC, are under the curve; CI, confidence interval; CL/F, oral clearance; Cmax, maximum plasma concentration; pharmacokinetics; T1/2, half-life; V/F, volume of distribution.
*Values presented as geometric mean (90% CI geometric mean).
‡ Data were not available for 1 patient.
§Data were not available for 2 patients.
¶N = 14.
[dbar]N = 6.